Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.71 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.65 |
| ▸ | TFEB | P19484 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3567982 | 1.00 | ABCG2 (0.71) | ABCG2NFE2L2TFEBCYP1A2CYP2D6 | |
| SCHEMBL14191358 | 0.91 | ABCG2 (0.61) | ABCG2NFE2L2TFEBCYP1A2CYP2D6 | |
| SCHEMBL28993538 | 0.89 | ABCG2 (0.63) | ABCG2NFE2L2TFEBCYP1A2CYP2D6 | |
| SCHEMBL18513242 | 0.88 | NFE2L2 (0.61) | ABCG2NFE2L2TFEBCYP1A2CYP2D6 | |
| SCHEMBL16382580 | 0.87 | ABCG2 (0.56) | ABCG2NFE2L2TFEBCYP1A2CYP2D6 | |
| SCHEMBL16587940 | 0.86 | ABCG2 (0.69) | ABCG2NFE2L2TFEBCYP1A2CYP2D6 | |
| SCHEMBL16265418 | 0.86 | ABCG2 (0.69) | ABCG2NFE2L2TFEBCYP1A2CYP2D6 | |
| SCHEMBL16265416 | 0.86 | ABCG2 (0.69) | ABCG2NFE2L2TFEBCYP1A2CYP2D6 | |
| SCHEMBL20123366 | 0.85 | ABCG2 (0.67) | ABCG2NFE2L2TFEBCYP1A2CYP2D6 | |
| SCHEMBL7954649 | 0.85 | ABCG2 (0.67) | ABCG2NFE2L2TFEBCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | disclosed |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2020-03-03 | — | — | US | disclosed |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2019-08-01 | — | — | US | disclosed |
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180078535-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-03-22 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2004-09-09 | — | — | US | disclosed |
| US-6664272-B2 | Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue | EMORY UNIVERSITY | 2003-12-16 | — | — | US | disclosed |
| EP-1242379-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | Emory University (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001040188-A9 | CURCUMIN ANALOGUES FOR TREATING CANCER | UNIV EMORY (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2002-02-14 | — | — | US | disclosed |
| WO-2001040188-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | EMORY UNIVERSITY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | ABCG2 842/4885NFE2L2 832/4885TFEB 414/4885 |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | ABCG2 629/4885NFE2L2 1139/4885TFEB 705/4885 |
| US-20180078535-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | ABCG2 629/4885NFE2L2 1139/4885TFEB 705/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | ABCG2 2380/4885NFE2L2 75/4885TFEB 19/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | ABCG2 842/4885NFE2L2 832/4885TFEB 414/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | ABCG2 842/4885NFE2L2 832/4885TFEB 414/4885 |
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | ABCG2 175/4885NFE2L2 137/4885TFEB 265/4885 |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | ABCG2 629/4885NFE2L2 1139/4885TFEB 705/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | ABCG2 842/4885NFE2L2 832/4885TFEB 414/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | ABCG2 842/4885NFE2L2 832/4885TFEB 414/4885 |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | ABCG2 629/4885NFE2L2 1139/4885TFEB 705/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | ABCG2 4415/4885NFE2L2 5/4885TFEB 346/4885 |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | ABCG2 175/4885NFE2L2 137/4885TFEB 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.